SCHEMBL2054423

SCHEMBL2054423

Cc1ccc2c(Nc3cc(C(NC(=O)O)C(C)(C)C)ccc3Sc3ccccc3)ccnc2n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.38
AKT2 P31751 1/20 0.38
MAPT P10636 3/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
PDE2A O00408 3/20 0.31
TRPV1 Q8NER1 1/20 0.31
POLB P06746 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
ADORA2A P29274 2/20 0.30
ADORA1 P30542 2/20 0.30
EGLN2 Q96KS0 1/20 0.30
EGLN1 Q9GZT9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2018796 0.81 PIM1 (0.42) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2969129 0.80 ABCG2 (0.42) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL13273825 0.80 PIM1 (0.41) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2054424 0.80 PIM1 (0.39) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2961780 0.79 PIM1 (0.39) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2961779 0.79 PIM1 (0.41) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2971914 0.79 PIM1 (0.45) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2960981 0.78 PIM1 (0.43) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL13273746 0.78 PIM1 (0.40) PIM1AKT2MAPTLMNASMN1; SMN2
SCHEMBL2968817 0.78 TDP1 (0.43) PIM1AKT2MAPTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160233-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160233-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885MAPT 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.